Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study

• Published in: The Journal of urology Vol. 154; no. 3; p. 1017
• Main Authors: Shenfeld, O, Hanani, J, Shalhav, A, Vardi, Y, Goldwasser, B
• Format: Journal Article
• Language: English
• Published: United States 01.09.1995
• Subjects: Adult; Aged; Alprostadil - administration & dosage; Double-Blind Method; Drug Combinations; Erectile Dysfunction - drug therapy; Humans; Impotence, Vasculogenic - drug therapy; Injections; Male; Middle Aged; Papaverine - administration & dosage; Penile Erection; Penis; Phentolamine - administration & dosage
• ISSN: 0022-5347
• DOI: 10.1016/S0022-5347(01)66964-7

A study was designed to compare intracorporeal injections of papaverine plus phentolamine (2-drug solution) and papaverine plus phentolamine and prostaglandin E1 (3-drug solution) for the treatment for impotence. A total of 20 impotent patients received intracorporeal injections of the 2-drug or 3-drug solution alternately during 2 sessions, and the quality and duration of erections were assessed. Of the patients 73% achieved a full erection with the 3-drug solution compared to 28% with the 2-drug solution. The average duration of erections was 57 minutes and 33.6 minutes, respectively. The complication rate was similar for the 2 treatments. Papaverine plus phentolamine and prostaglandin E1 is superior to papaverine plus phentolamine alone for the treatment of impotence.